In September, US 10-year Treasury yields jumped from 4.79% to 5.17%, driven mainly by rising real interest rates rather than inflation expectations. This reflects confidence in the Federal Reserve's monetary policy and is fueled by a robust investment boom in the US, especially in the technology sector. In contrast, Europe shows limited investment growth, with Euro-area rates hitting capacity, which restricts further ECB tightening and makes European government bonds more attractive than US Treasuries. Investors are advised to maintain exposure to US growth stocks, selectively favor European exporters, and use currency hedges to optimize returns across regions.
The story about US and European economic dynamics is presented with Pluang market data for context. For readers following US stocks, here is Pluang's market snapshot as of Sep 27, 2026 17:11 WIB: out of 150 priced US stocks, 87 rose and 61 fell. Notable movers include BlackBerry Limited (USD 8.21, -5.96%), Roblox Corp (USD 46.44, -4.89%), and PayPal Holdings, Inc. (USD 55.04, +4.64%).
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
Hayati®, a UK-based technology and vaping brand, partnered with elrow at the Edinburgh Festival to launch the "TURN UP WITH HAYATI®" activation. This collaboration featured a dedicated space with interactive activities, special festival edition produ...
Wormhole (W) has fallen about 10% recently, driven mainly by large investors (whales) selling on OKX, while Binance whales are accumulating. The Funding Rate shows reduced bearish pressure, improving from -0.0484% to -0.0083%, indicating a gradual bu...
Zealand Pharma announced positive topline results from the multiple ascending dose part of its Phase 1 trial for ZP9830, a novel Kv1.3 ion channel blocker targeting autoimmune diseases. The drug was well tolerated with no serious adverse events in 32...
